Arrys Therapeutics   Report issue

For profit Phase 2
Founded: Cambridge MA United States (2017)
Status: Acquired by Ikena Oncology (2018)

Organization Overview

First Clinical Trial
2018
NCT03658772
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Arrys Therapeutics